Lenzilumab
- Generic Name
- Lenzilumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1229575-09-0
- Unique Ingredient Identifier
- IE4X6497XK
- Background
Lenzilumab is under investigation in clinical trial NCT02546284 (Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)).
- Associated Conditions
- -
- Associated Therapies
- -
COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 441
- Registration Number
- NCT04534725
- Locations
- ๐ฆ๐บ
St Vincent's Hospital, Fitzroy, Victoria, Australia
๐ฆ๐บPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia
๐ฆ๐บRoyal Melbourne Hospital, Melbourne, Victoria, Australia
Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Humanigen, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02546284
- Locations
- ๐บ๐ธ
Moffitt Cancer Center, Tampa, Florida, United States
๐บ๐ธMayo Clinic Cancer Center Clinical Research, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath